F-Prime Capital, Forbion, and Norwest led a $157m Series B round in Engrail Therapeutics.

F-Prime Capital, Forbion, and Norwest, three investors, led a $157m Series B round in Engrail Therapeutics, a neuroscience company focused on the development of transformational therapies, with participation from RiverVest Venture Partners, Red Tree Venture Capital, abrdn, Ysios Capital, Longwood Fund, Eight Roads Ventures, and Pivotal Life Sciences. “With strong financial backing from highly sophisticated and dedicated life science investors, we are well positioned to deliver multiple value-creating milestones. Notably, we look forward to completing our ongoing ENX-102 phase 2 study in generalized anxiety disorder and advancing the rest of our pipeline into clinical development. Engrail was fortunate to have been incubated under a tremendous commitment from Pivotal Life Sciences. We are excited to start the next chapter of our journey with some of the best thought partners in neuroscience and life sciences investing in our success," Vikram Sudarsan, Engrail Therapeutics President and CEO.